Prescribing overview
An equine oral antiprotozoal for EPM caused by Sarcocystis neurona. Neurologic improvement and parasite control are separate outcomes.
EPM requires a neurologic workup because other diseases can cause incoordination. Ponazuril targets the parasite; clearing infection may leave deficits from existing injury. Record baseline gait and strength so follow-up assesses function rather than assuming that completion of treatment means recovery.
Key prescribing checks
- Review the source-specific safety card and monitoring plan before use.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Horses
U.S. labeled/regulatory equine use; see exact scopeTreatment of equine protozoal myeloencephalitis caused by Sarcocystis neurona
U.S. equine paste indication; no dog, cat or other-species approval is inferred.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Antiprotozoal activity against S. neurona was demonstrated in cell culture; the approval evaluation combined laboratory activity, equine exposure and clinical neurologic response.
Absorption, distribution, metabolism and elimination
Repeated oral administration produces measurable serum and cerebrospinal-fluid concentrations. The current label distinguishes initial loading from maintenance administration; use its current instructions rather than an older regimen.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Marquis
U.S. Marquis oral paste for horses.
Contraindications · when not to use
A formal contraindication list is not established in the reviewed source for this scope. This does not establish safety; confirm the exact product and full labeling.
Precautions & monitoring
- Not for horses intended for human consumption. Breeding, pregnancy and lactation safety have not been evaluated.
- Early worsening of ataxia has been reported; improvement may be incomplete.
This is a selected source summary, not exhaustive prescribing guidance.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Field observations included oral blisters, rash or hives, loose stool, colic and a seizure; causal association was not established.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No numerical regimen is reproduced here. Verify the current Marquis loading and maintenance instructions, exact weight and syringe calibration before prescribing.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Marquis
U.S. Marquis oral paste for horses.
- Safety with concomitant equine therapies has not been evaluated; absence of a listed pair is not clearance.
Monitoring
Compare neurologic examination and functional ability with baseline; investigate deterioration promptly.
Client counseling
Complete the prescribed course. Report worsening coordination, falls, appetite changes or diarrhea.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Follow syringe storage and assembly instructions; discard partially used syringes after the prescribed course.
Brands, formulations & ingredient identity
Active ingredients
Ponazuril
Other searchable names: Marquis
The reviewed product is Marquis oral paste. Bulk compounding ingredients are not the same approved presentation.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Marquis
- Formulation
- 15% ponazuril oral paste
- Label / product scope
- Horses
Equine EPM product.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →